ICPT Intercept Pharmaceuticals Inc

Price (delayed)

$21.66

Market cap

$715.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.34

Enterprise value

$1.21B

Sector: Healthcare
Industry: Biotechnology

Highlights

ICPT's revenue is up by 24% year-on-year and by 3.9% since the previous quarter
Intercept Pharmaceuticals's gross profit has increased by 24% YoY and by 4.6% QoQ
The quick ratio has declined by 32% year-on-year and by 12% since the previous quarter
The equity has contracted by 28% from the previous quarter

Key stats

What are the main financial stats of ICPT
Market
Shares outstanding
33.02M
Market cap
$715.12M
Enterprise value
$1.21B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
Earnings
Revenue
$312.69M
EBIT
-$226.83M
EBITDA
-$217.57M
Free cash flow
-$173.92M
Per share
EPS
-$8.34
Free cash flow per share
-$5.28
Book value per share
-$5.06
Revenue per share
$9.48
TBVPS
$17.61
Balance sheet
Total assets
$580.49M
Total liabilities
$747.34M
Debt
$560.58M
Equity
-$166.85M
Working capital
$366.67M
Liquidity
Debt to equity
-3.36
Current ratio
3.05
Quick ratio
2.9
Net debt/EBITDA
-2.27
Margins
EBITDA margin
-69.6%
Gross margin
98.3%
Net margin
-87.9%
Operating margin
-74%
Efficiency
Return on assets
-44.5%
Return on equity
N/A
Return on invested capital
-23.9%
Return on capital employed
-56.5%
Return on sales
-72.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ICPT stock price

How has the Intercept Pharmaceuticals stock price performed over time
Intraday
-6.03%
1 week
-30.55%
1 month
-35.88%
1 year
-75.86%
YTD
-12.31%
QTD
-12.31%

Financial performance

How have Intercept Pharmaceuticals's revenue and profit performed over time
Revenue
$312.69M
Gross profit
$307.37M
Operating income
-$231.24M
Net income
-$274.88M
Gross margin
98.3%
Net margin
-87.9%
Intercept Pharmaceuticals's operating margin has increased by 40% YoY and by 20% QoQ
ICPT's net margin is up by 36% year-on-year and by 18% since the previous quarter
Intercept Pharmaceuticals's operating income has increased by 26% YoY and by 17% QoQ
ICPT's revenue is up by 24% year-on-year and by 3.9% since the previous quarter

Growth

What is Intercept Pharmaceuticals's growth rate over time

Valuation

What is Intercept Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
The EPS has grown by 23% year-on-year and by 15% since the previous quarter
The equity has contracted by 28% from the previous quarter
ICPT's price to sales (P/S) is 98% lower than its 5-year quarterly average of 150.3 and 55% lower than its last 4 quarters average of 5.1
ICPT's revenue is up by 24% year-on-year and by 3.9% since the previous quarter

Efficiency

How efficient is Intercept Pharmaceuticals business performance
The ROS has grown by 40% year-on-year and by 20% since the previous quarter
Intercept Pharmaceuticals's return on invested capital has increased by 21% YoY and by 14% QoQ
Intercept Pharmaceuticals's return on assets has increased by 8% QoQ and by 8% YoY

Dividends

What is ICPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICPT.

Financial health

How did Intercept Pharmaceuticals financials performed over time
The total assets is 22% smaller than the total liabilities
The quick ratio has declined by 32% year-on-year and by 12% since the previous quarter
Intercept Pharmaceuticals's current ratio has decreased by 31% YoY and by 11% from the previous quarter
Intercept Pharmaceuticals's debt to equity has shrunk by 133% YoY but it has increased by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.